Health Care & Life Sciences » Biotechnology | Critical Outcome Technologies Inc.

Critical Outcome Technologies Inc. | Income Statement

Fiscal year is May-April. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
30.60
-
-
-
-
218.80
Cost of Goods Sold (COGS) incl. D&A
-
534.80
536.50
216.20
249.40
218.80
Gross Income
-
534.80
536.50
216.20
249.40
218.80
SG&A Expense
2,338.70
2,594.40
3,447.00
3,818.00
6,834.50
6,101.30
EBIT
2,828.70
3,129.20
3,983.50
4,034.20
7,083.90
6,320.10
Unusual Expense
-
-
235.10
965.90
631.10
1,438.60
Non Operating Income/Expense
67.70
29.50
143.00
49.30
102.10
45.40
Interest Expense
-
20.20
64.20
4.20
2.40
2.60
Pretax Income
2,753.70
3,114.30
3,942.90
5,037.80
6,353.10
4,924.30
Income Tax
127.90
118.10
129.70
113.40
144.20
43.90
Consolidated Net Income
2,625.80
2,996.20
3,813.20
4,924.40
6,208.90
4,880.40
Net Income
2,625.80
2,996.20
3,813.20
4,924.40
6,208.90
4,880.40
Net Income After Extraordinaries
2,625.80
2,996.20
3,813.20
4,924.40
6,208.90
4,880.40
Net Income Available to Common
2,625.80
2,996.20
3,813.20
4,924.40
6,208.90
4,880.40
EPS (Basic)
0.30
0.30
0.40
0.40
0.42
0.31
Basic Shares Outstanding
7,534.50
8,919.60
10,869.10
12,710.30
14,841.80
15,967.90
EPS (Diluted)
0.35
0.34
0.35
0.39
0.42
0.31
Diluted Shares Outstanding
7,534.50
8,919.60
10,869.10
12,710.30
14,841.80
15,967.90
EBITDA
2,308.20
2,594.40
3,447.00
3,818.00
6,834.50
6,101.30
Non-Operating Interest Income
7.20
5.50
12.80
15.80
-
5.30

About Critical Outcome Technologies

View Profile
Address
Canadian Venture Building
Toronto Ontario M5C 1P1
Canada
Employees -
Website http://cotingapharma.com
Updated 07/08/2019
Cotinga Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of cancer and other unmet medical needs. Its lead product candidate, COTI-2, treats ovarian and other gynecological cancers and restores normal cell signaling in cancer with p53 mutations. The company was founded on October 13, 2006 and is headquartered in London, Canada.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.